Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea
Observational
OA: closed
CC0
⤵ 21 in-corpus citations
AI-generated summary
This study measured eicosanoids and platelet-activating factor in menstrual blood, finding significantly higher concentrations in women with primary dysmenorrhea compared to controls.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Prostanoids, leukotrienes and platelet-activating factor were measured by radioimmunoassay in menstrual blood of seven women with primary dysmenorrhea and five healthy controls. The eicosanoids and PAF concentrations in dysmenorrheic patients were significantly higher than those found in healthy women (P less than 0.005 for PGF2 alpha, 11-dehydro-TXB2, 2,3-dinor-TXB2 and LTC4/D4; P less than 0.001 for PAE; P less than 0.05 for PGE2 and 2,3-dinor-6-keto-PGF1 alpha). Whereas no relationship could be found between the concentrations of PGF2 alpha, PGE2, 11-dehydro- and 2,3-dinor-TXB2 and severity of primary dysmenorrhea, a close correlation between LTC4/D4 and PAF and severity of the disease was observed, particularly in patients who responded poorly to therapy with prostaglandin synthetase inhibitors. We conclude that the hyperstimulation of myometrial activity is not caused by selective stimulation of one metabolic pathway of arachidonic acid, but rather by an overall stimulation of phospholipid metabolism. The assessment of prostanoids, leukotrienes and PAF in menstrual blood many be useful as a direct index of primary dysmenorrhea, and the development of their antagonists may have therapeutic implications in improved treatment of the disease.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (18)
- Investigational drugs for the treatment of dysmenorrhea 2024
- Association of endocannabinoids with pain in endometriosis 2021
- Dysmenorrhea, endometriosis, adenomyosis: clinical and pathogenetic relationships 2018
- DYSMENORRHEA, ADENOMYOSIS, ENDOMETRIOSIS, TUMOR PROCESS: CAUSATION 2017
- Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium 2017
- Menstrual pain and epithelial ovarian cancer risk 2014
- Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats? 2014
- Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies 2012
- Chronic pelvic pain in the adolescent 2012
- Studying the Effect of Montelukast in the Treatment of Dysmenorrhea: A single-Blind, Placebo-controlled Trial 2012
- Efficacy of montelukast, a leukotriene receptor antagonist, for the treatment of dysmenorrhea: a prospective, double-blind, randomized, placebo-controlled study 2009
- Dysmenorrhea in adolescents and young adults: from pathophysiology to pharmacological treatments and management strategies 2008
- The Management of Chronic Pelvic Pain 2008
- Dysmenorrhea in adolescents and young adults: etiology and management 2006
- Painful menstruation 2005
- Dysmenorrhea treatment with a single daily dose of rofecoxib 2003
- A contemporary approach to dysmenorrhea in adolescents 2002
- Leukotrienes in gynaecology: the hypothetical value of anti-leukotriene therapy in dysmenorrhoea and endometriosis 2000
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:04:39.942088+00:00
License: CC0
· commercial use OK